Duality Biotherapeutics, Inc. (9606) Stock Statistics & Valuation Metrics

Duality Biotherapeutics, Inc. has a market cap or net worth of HK$28.17B. The enterprise value is HK$5.84B.

Duality Biotherapeutics, Inc. has 88,036,260 shares outstanding. The number of shares has decreased by -2.65% in one year.

Duality Biotherapeutics, Inc.’s return on equity (ROE) is 0.52 and return on invested capital (ROIC) is 11.00%.

The current PE Ratio of Duality Biotherapeutics, Inc. is ―. Duality Biotherapeutics, Inc.’s PEG ratio is -0.08.

In the last 12 months, Duality Biotherapeutics, Inc. had revenue of 1.94B and earned -1.05B in profits. Earnings per share was -12.63.

In the last 12 months, operating cash flow was 855.12M and capital expenditures -10.06M, giving a free cash flow of 845.06M billion.

Duality Biotherapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Duality Biotherapeutics, Inc. upcoming earnings date is Aug 26, 2025, TBA (Confirmed).

Duality Biotherapeutics, Inc. as a current ratio of 0.49, with Debt / Equity ratio of 2.33%

In the past 12 months, Duality Biotherapeutics, Inc. has paid 35.89M in taxes.

Duality Biotherapeutics, Inc. EV to EBITDA ratio is -14.72, with an EV/FCF ratio of 58.17.

Duality Biotherapeutics, Inc. has HK$3.70B in cash and marketable securities with HK$67.89M in debt, giving a net cash position of HK$3.63B billion.

Gross margin is 45.23%, with operating margin of -9.74%, and net profit margin of -54.11%.

The average price target for Duality Biotherapeutics, Inc. is HK$430.03, which is 11.43% higher than the current price. The consensus rating is Moderate Buy